Allergy Therapeutics plc
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0 GBP
−40.13 M GBP
55.04 M GBP
321.58 M
About Allergy Therapeutics plc
Sector
Industry
CEO
Manuel Llobet
Website
Headquarters
Worthing
Founded
2004
IPO date
Oct 11, 2004
Identifiers
2
ISIN GB00B02LCQ05
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company was founded by Keith Iain Carter in 1998 and is headquartered in Worthing, the United Kingdom.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AGY is 10.3 GBX — it has increased by 2.86% in the past 24 hours. Watch Allergy Therapeutics plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Allergy Therapeutics plc stocks are traded under the ticker AGY.
AGY stock has fallen by −9.24% compared to the previous week, the month change is a −10.74% fall, over the last year Allergy Therapeutics plc has showed a 73.90% increase.
We've gathered analysts' opinions on Allergy Therapeutics plc future price: according to them, AGY price has a max estimate of 13.00 GBX and a min estimate of 13.00 GBX. Watch AGY chart and read a more detailed Allergy Therapeutics plc stock forecast: see what analysts think of Allergy Therapeutics plc and suggest that you do with its stocks.
AGY stock is 5.70% volatile and has beta coefficient of 1.10. Track Allergy Therapeutics plc stock price on the chart and check out the list of the most volatile stocks — is Allergy Therapeutics plc there?
Today Allergy Therapeutics plc has the market capitalization of 663.28 M, it has decreased by −4.39% over the last week.
Yes, you can track Allergy Therapeutics plc financials in yearly and quarterly reports right on TradingView.
Allergy Therapeutics plc is going to release the next earnings report on Feb 26, 2026. Keep track of upcoming events with our Earnings Calendar.
AGY net income for the last half-year is −29.05 M GBP, while the previous report showed −11.09 M GBP of net income which accounts for −162.04% change. Track more Allergy Therapeutics plc financial stats to get the full picture.
No, AGY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Allergy Therapeutics plc EBITDA is −25.23 M GBP, and current EBITDA margin is −46.02%. See more stats in Allergy Therapeutics plc financial statements.
Like other stocks, AGY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Allergy Therapeutics plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Allergy Therapeutics plc technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Allergy Therapeutics plc stock shows the buy signal. See more of Allergy Therapeutics plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.